ESC 365 - Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT) Study

ESC Premium Access

Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT) Study

Session: Poster session 4 - Atrial fibrillation obesity

Topic: Atrial fibrillation (AF)

Speaker: Ms J. Neefs (Amsterdam, NL)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Ms Jolien Neefs

Academic Medical Centre, Amsterdam (Netherlands (The))

0 follower

14 more presentations in this session

Alogliptin, a DPP-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits

Speaker: Doctor T. Liu (Tianjin, CN)

C(-915)G polymorphism gene of transforming growth factor 1 in patients with metabolic syndrome and atrial fibrillation

Speaker: Assistant Professor V. Ionin (Saint-Petersburg, RU)

Epicardial obesity as a significant predictor of atrial fibrillation

Speaker: Doctor A. Ott (Barnaul, RU)

Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial.

Speaker: Doctor T. Pol (Uppsala, SE)

Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry

Speaker: Doctor S. Goldhaber (Boston, US)

Access the full session

Poster session 4 - Atrial fibrillation obesity

Speakers: Ms J. Neefs, Doctor T. Liu, Assistant Professor V. Ionin, Doctor A. Ott, Doctor T. Pol...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources